Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus

ConclusionsThrough the evaluation up to 672  days, semaglutide, liraglutide, and empagliflozin decreased the risk of MACE. Concerning the risk of each cardiovascular event, risk reduction was seen with empagliflozin and canagliflozin.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research